Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Helicobacter Pylori.

Chey1

  • 1University of Michigan Medical Center, 3912 Taubman Center, Box 0362, Ann Arbor, MI 48109.

Current Treatment Options in Gastroenterology
|November 30, 2000
PubMed
Summary

All patients with peptic ulcers require H. pylori treatment. Current triple therapies are standard, but dual therapies are discouraged due to emerging antibiotic resistance, necessitating careful treatment selection.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Case of the month

The American journal of medicine·2000
Same author

Dynamics of rough Ge(001) surfaces at low temperatures.

Physical review letters·1996
Same author

Surface morphology of Ge(001) during etching by low-energy ions.

Physical review. B, Condensed matter·1995
Same author

Surface morphology during multilayer epitaxial growth of Ge(001).

Physical review letters·1995

Area of Science:

  • Gastroenterology
  • Microbiology
  • Pharmacology

Background:

  • Helicobacter pylori (H. pylori) infection is a primary cause of peptic ulcer disease.
  • Treatment guidelines for H. pylori are evolving, particularly concerning its role in non-ulcer dyspepsia and in patients with risk factors for gastric cancer.
  • Antibiotic resistance to H. pylori is a growing concern, impacting treatment efficacy.

Purpose of the Study:

  • To review current H. pylori treatment strategies.
  • To discuss the efficacy and limitations of various therapeutic regimens.
  • To highlight the impact of antibiotic resistance on treatment outcomes.

Main Methods:

  • Review of current clinical guidelines and relevant literature on H. pylori eradication therapies.
  • Analysis of the effectiveness of triple and dual therapies, including proton pump inhibitor-based and bismuth-based regimens.
  • Discussion of geographical variations in antibiotic resistance, specifically for metronidazole and clarithromycin.

Main Results:

  • Triple therapies (proton pump inhibitor or ranitidine bismuth citrate with two antibiotics) are the standard of care for H. pylori.
  • Dual therapies are no longer recommended for H. pylori eradication.
  • Bismuth triple therapy offers a cost-effective alternative but has drawbacks like side effects and dosing frequency.
  • Treatment durations vary by region, with 7 days recommended in Europe and 10-14 days in the United States.
  • Metronidazole resistance is geographically variable and reduces treatment effectiveness; clarithromycin resistance is currently less frequent but may be increasing.

Conclusions:

  • H. pylori eradication is crucial for patients with peptic ulcers.
  • Treatment selection should consider local antibiotic resistance patterns and patient factors.
  • Retreatment regimens should avoid previously used antibiotics to overcome resistance and ensure eradication.

Related Experiment Videos